Studies have shown that S100A8- and S100A9-mediated inflammation can alter hepatic lipid metabolism by increasing lipogenesis and decreasing cholesterol efflux, contributing to dyslipidemia (45, 46). The gene discussed is S100A8; the disease is metabolic syndrome.